Dialectical Behavior Therapy Compared With General Psychiatric Management for Borderline Personality Disorder: Clinical Outcomes and Functioning Over a 2-Year Follow-Up
Publication: American Journal of Psychiatry
Abstract
Objective:
The authors conducted a 2-year prospective naturalistic follow-up study to evaluate posttreatment clinical outcomes in outpatients who were randomly selected to receive 1 year of either dialectical behavior therapy or general psychiatric management for borderline personality disorder.
Method:
Patients were assessed by blind raters 6, 12, 18, and 24 months after treatment. The clinical effectiveness of treatment was assessed on measures of suicidal and nonsuicidal self-injurious behaviors, health care utilization, general symptom distress, depression, anger, quality of life, social adjustment, borderline psychopathology, and diagnostic status. The authors conducted between-group comparisons using generalized estimating equation, mixed-effects models, or chi-square statistics, depending on the distribution and nature of the data.
Results:
Both treatment groups showed similar and statistically significant improvements on the majority of outcomes 2 years after discharge. The original effects of treatment did not diminish for any outcome domain, including suicidal and nonsuicidal self-injurious behaviors. Further improvements were seen on measures of depression, interpersonal functioning, and anger. However, even though two-thirds of the participants achieved diagnostic remission and significant increases in quality of life, 53% were neither employed nor in school, and 39% were receiving psychiatric disability support after 36 months.
Conclusions:
One year of either dialectical behavior therapy or general psychiatric management was associated with long-lasting positive effects across a broad range of outcomes. Despite the benefits of these specific treatments, one important finding that replicates previous research is that participants continued to exhibit high levels of functional impairment. The effectiveness of adjunctive rehabilitation strategies to improve general functioning deserves additional study.
While several studies have established the effectiveness of cognitive-behavioral and psychodynamic treatments of borderline personality disorder, relatively few have addressed the long-term effects of these treatments. With a few exceptions (1–3), the duration of follow-up in these treatment studies has been short (<1 year). Conclusions about effectiveness require information on the sustained effects of treatment. Although dialectical behavior therapy is a multimodal cognitive-behavioral approach that has the largest empirical base of any psychosocial treatment for borderline personality disorder, the follow-up time frames in the five controlled trials evaluating the lasting effects of this treatment were 1 year or less (4–8). The available long-term data reveal a mixed picture, with some evidence suggesting that the strength of the treatment effects on some outcomes diminishes by 6 months after discharge (4, 6, 8).
We report the results of a 2-year naturalistic follow-up study of 180 individuals enrolled in a randomized controlled trial in Toronto between 2003 and 2006. The design, procedures, and treatment outcomes of the original study are described elsewhere (9). Briefly, patients diagnosed with borderline personality disorder were randomly assigned to receive 1 year of outpatient treatment consisting of either dialectical behavior therapy or general psychiatric management. After discharge, participants in both groups showed significant improvements on a broad range of clinical outcomes, including suicidal and nonsuicidal self-injurious behaviors, health care utilization (emergency department visits, inpatient days, and psychotropic medication use), borderline psychopathology, symptom distress, depression, interpersonal functioning, and anger. There were no differences between the treatment groups in clinical outcomes.
In the present study, we prospectively evaluated whether these effects were sustained 2 years after treatment (i.e., 3 years after random assignment to a treatment group). Consistent with the original study, our primary outcome measures were the frequency and severity of suicidal and nonsuicidal self-injurious behaviors. We also examined health care utilization, symptom distress, anger, depression, interpersonal functioning, overall quality of life, borderline psychopathology, and remission from borderline personality disorder. Finally, given accumulating evidence from long-term follow-up studies of borderline personality disorder that show persistent impairment in social functioning (10–12), we also examined overall functioning.
Method
In the original study, 180 adults meeting DSM-IV criteria (13) for borderline personality disorder were randomly assigned to 1 year of either dialectical behavior therapy (N=90) or general psychiatric management (N=90). Participants were between 18 and 60 years old and had at least two suicidal or nonsuicidal self-injurious episodes in the past 5 years, with at least one occurring in the past 3 months. Exclusion criteria included substance dependence in the preceding 30 days; a diagnosis of psychotic disorder, bipolar I disorder, delirium, dementia, or mental retardation; a medical condition that precluded psychiatric medications; a serious medical condition requiring hospitalization within the coming year; living outside of a 40-mile radius of Toronto; and having plans to leave the province in the next 2 years.
Dialectical behavior therapy was implemented according to the treatment manuals (14, 15). General psychiatric management was implemented as a comprehensive approach to borderline personality disorder, developed and manualized for this trial, consisting of psychodynamic psychotherapy, case management, and pharmacotherapy (P.S. Links, Y. Bergmans, J. Novick, J. LeGris, unpublished 2009 manuscript). The psychotherapeutic model in this approach emphasized the relational aspects of the disorder and focused on disturbed attachment patterns and the enhancement of emotion regulation in relationships. Case management strategies were integrated into weekly individual sessions. No restrictions were placed on ancillary pharmacotherapy in either condition; in general, pharmacotherapy was based on a symptom-targeted approach but prioritized mood lability, impulsivity, and aggressiveness as presented in APA guidelines (16).
Therapists in both treatment arms were well experienced in the treatment of borderline personality disorder, were trained in their respective approaches, and attended weekly supervision meetings. Treatment fidelity was evaluated using modality-specific adherence scales (17).
All participants underwent 24 months of naturalistic posttreatment follow-up, regardless of whether they completed treatment. Assessments were conducted 18, 24, 30, and 36 months after random treatment assignment, with the exception of the International Personality Disorder Examination (18), which was administered only at 24 and 36 months. Assessments were conducted by a board-certified psychiatrist and doctoral-level clinicians who were blinded to treatment group. Interrater reliability was maintained on assessment of borderline personality disorder diagnostic criteria (intraclass correlation coefficients, 0.83–0.92), and treatment history data were collected by an unblinded study coordinator.
Although participants were required to discontinue the study treatment at the end of 1 year, three patients in the general psychiatric management arm received an additional 3, 14, and 24 months, respectively, because of therapist concerns about the risks of discontinuing treatment. To determine whether this protocol violation caused meaningful differences in the results, we conducted outcome analyses with and without the inclusion of these three patients.
The study protocol was approved by each center's research ethics board, and participants provided written informed consent for follow-up before enrolling in the original study. Participants were compensated $10/hour for completing each assessment.
Assessments
The follow-up study included the same measures as the original study. As before, the primary outcome measures were the frequency and severity of suicidal and nonsuicidal self-injurious behaviors, as assessed with the Suicide Attempt Self-Injury Interview (19). To determine whether any of the participants who failed to complete the 36-month follow-up assessment had died by suicide, we searched the Ontario death registry.
Secondary outcome measures included health care utilization, borderline personality symptom severity, symptom distress, anger, depression, interpersonal functioning, and quality of life. We measured health care utilization using the semistructured Treatment History Interview (M.M. Linehan, H.L. Heard, unpublished 1987 manuscript) to obtain self-reported counts of the number of admissions to and number of days in a psychiatric hospital, emergency department visits, medication use, outpatient psychosocial and psychiatric treatment, and use of community and crisis support services. Other secondary outcome measures included the total score on the Zanarini Rating Scale for Borderline Personality Disorder (20); the global score on the Symptom Checklist 90–Revised (SCL-90-R; 21); the expressed anger subscore on the State-Trait Anger Expression Inventory (22); the total score on the Beck Depression Inventory-II (BDI-II; 23); and the total score on the Inventory of Interpersonal Problems (24). The International Personality Disorder Examination (18) was used to assess remission; consistent with a major prospective follow-up study (10), remission was defined as meeting no more than two criteria for borderline personality disorder for 1 year.
Overall functioning was assessed based on the EuroQol-5D (25) thermometer, a measure of health-related quality of life and overall disability, occupational functioning, and receipt of psychiatric disability benefits. Additionally, we assessed whether participants attained normal functioning in terms of their level of symptom distress severity (i.e., SCL-90-R) at 24 and 36 months.
Statistical Analysis of Change
We conducted analyses on both the intent-to-treat population (N=180) and on the per protocol population, defined as the 167 participants who attended at least eight treatment sessions (dialectical behavior therapy, N=85; general psychiatric management, N=82). All primary and secondary outcomes were reanalyzed without data from the three participants who received study treatment during the follow-up phase to determine whether this altered study results.
Several count measures, such as self-harm behaviors, hospitalization days, and emergency department visits, were nonnormally distributed and therefore analyzed using a negative binomial distribution.
We analyzed outcomes that were nonnormally distributed using a generalized estimating equation model, which accounts for collinearity between repeated measurements (26). Normally distributed outcomes were analyzed using mixed-effects growth curve models. Using these methods, the statistics are based on full information, since participants with partially missing data were included in the analyses.
We analyzed changes between the treatment and follow-up phases on normally distributed outcomes using a piecewise linear response for rate; negative binomial-distributed outcomes were analyzed using step functions for level of response. We modeled each outcome using an initial intercept, a rate or level of improvement for the treatment phase, and a separate rate or level of change for the follow-up phase; each model included a term within each period for a between-group difference in rate.
Chi-square tests were used to compare between-group differences in categorical responses (e.g., number of participants meeting borderline personality disorder criteria at endpoints). We used the twofold criterion of Jacobson et al. (27) to assess clinically significant improvement based on general psychopathology. For these analyses, the SCL-90-R global severity index was selected as the metric because it had been used in two previous trials of dialectical behavior therapy (3, 28). The criteria for clinically significant change were 1) individual shifts from the dysfunctional to the functional range based on nonclinical population norms (i.e., clinically significant improvement) and 2) a statistically reliable magnitude of change, defined as a difference greater than 1.96 standard errors of measurement estimated from Cronbach's alpha with our baseline data. Participants had to meet both criteria to be classified as achieving clinically significant change. To correct for multiple testing, the Holms-Bonferroni correction was applied, and a threshold of p<0.0015 was considered significant.
Results
Of the 180 participants who entered the original study, 30 (16.7%) failed to attend any follow-up assessments; 131 (73%), 128 (71%), 118 (66%), and 110 (61%) completed assessments at 18, 24, 30, and 36 months, respectively. Completion of all four follow-up assessments was achieved by 87 participants (48%). There were no statistically significant differences between groups in the loss to follow-up (dialectical behavior therapy, N=18/90 [20%] compared with general psychiatric management, N=12/90 [13%]). Overall, participants completed an average of 3.51 out of four assessments (SD=0.89). There were no between-group differences in the number of follow-up assessments attended (dialectical behavior therapy, N=2.53, SD=1.62; general psychiatric management, N=2.88, SD=1.44).
The characteristics of the original 180 participants are described in detail elsewhere (9). Briefly, they were 30.4 years old on average (SD=9.9) and were mostly women (86.1%); two-thirds (65.0%) were unemployed, and less than half (42.2%) had a college education. With one exception, there were no differences in demographic and diagnostic data, or suicidal and nonsuicidal self-injurious behaviors at baseline between participants who attended one or more follow-up assessments and those lost to follow-up. The prevalence of cluster C personality disorders was higher in those who attended one or more follow-up assessments than those lost to follow-up (44.0% compared with 23.3%, p=0.04).
Treatment Received During Follow-Up
Table 1 presents findings on the utilization of mental health care services during the follow-up phase. The proportion of participants utilizing psychosocial treatments ranged from 51.1% to 62.1% in the dialectical behavior therapy group and from 54.2% to 58.6% in the general psychiatric management group across follow-up assessments. The overall number of psychosocial treatments used by both groups increased significantly from the end of treatment (z=3.28, p=0.001). After correcting for multiple testing, no between-group differences were found (z=1.95, p=0.05).
| Treatment Group | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dialectical Behavior Therapy (N=90) | General Psychiatric Management (N=90) | Time Effecta | Group Effect | |||||||||||
| Health Care Utilization | Mean | SD | % | Mean | SD | % | Relative Rateb | 95% CI | z | p | Relative Rateb | 95% CI | z | p |
| Emergency department visits | ||||||||||||||
| Baseline | 1.99 | 3.01 | 66.7 | 2.08 | 3.53 | 57.8 | 0.77 | 0.56–1.06 | –1.60 | 0.11 | 0.82 | 0.52–1.32 | –0.81 | 0.42 |
| 12 months | 0.93 | 1.45 | 41.4 | 1.00 | 2.20 | 35.1 | ||||||||
| 18 months | 0.76 | 1.06 | 43.1 | 0.70 | 1.51 | 34.3 | ||||||||
| 24 months | 0.42 | 0.91 | 25.4 | 0.79 | 2.30 | 27.1 | ||||||||
| 30 months | 0.84 | 2.33 | 32.8 | 0.83 | 1.43 | 36.7 | ||||||||
| 36 months | 0.68 | 1.54 | 24.0 | 0.67 | 1.22 | 31.7 | ||||||||
| Emergency department visits for suicidal behavior | ||||||||||||||
| Baseline | 1.01 | 1.47 | 47.8 | 0.77 | 1.65 | 35.6 | 0.78 | 0.44–1.36 | –0.89 | 0.38 | 0.43 | 0.18–1.03 | –1.90 | 0.06 |
| 12 months | 0.41 | 1.00 | 20.0 | 0.29 | 1.13 | 13.0 | ||||||||
| 18 months | 0.16 | 0.59 | 10.3 | 0.23 | 0.89 | 10.0 | ||||||||
| 24 months | 0.10 | 0.30 | 10.2 | 0.24 | 0.79 | 12.9 | ||||||||
| 30 months | 0.12 | 0.59 | 5.2 | 0.18 | 0.70 | 8.3 | ||||||||
| 36 months | 0.30 | 1.22 | 6.0 | 0.20 | 0.58 | 13.3 | ||||||||
| Days in psychiatric hospital | ||||||||||||||
| Baseline | 10.52 | 24.42 | 31.1 | 8.90 | 25.16 | 33.0 | 1.17 | 0.62–2.19 | 0.49 | 0.63 | 0.95 | 0.33–2.74 | –0.09 | 0.93 |
| 12 months | 3.73 | 14.90 | 12.9 | 2.23 | 6.56 | 15.6 | ||||||||
| 18 months | 4.26 | 17.92 | 13.8 | 2.06 | 7.44 | 10.0 | ||||||||
| 24 months | 2.14 | 10.92 | 8.5 | 2.69 | 14.76 | 10.0 | ||||||||
| 30 months | 2.62 | 8.85 | 12.1 | 2.57 | 8.90 | 13.3 | ||||||||
| 36 months | 2.76 | 13.27 | 10.0 | 3.03 | 9.56 | 15.0 | ||||||||
| Number of psychiatric admissions | ||||||||||||||
| Baseline | 0.60 | 1.15 | 32.2 | 0.70 | 1.23 | 35.6 | 0.77 | 0.38–1.57 | –0.72 | 0.47 | 1.20 | 0.48–2.99 | 0.39 | 0.70 |
| 12 months | 0.21 | 0.66 | 11.5 | 0.29 | 0.81 | 12.8 | ||||||||
| 18 months | 0.22 | 0.70 | 13.8 | 0.16 | 0.58 | 10.0 | ||||||||
| 24 months | 0.10 | 0.36 | 8.5 | 0.11 | 0.36 | 10.0 | ||||||||
| 30 months | 0.24 | 0.80 | 12.1 | 0.20 | 0.71 | 13.3 | ||||||||
| 36 months | 0.22 | 0.91 | 10.0 | 0.42 | 1.85 | 15.0 | ||||||||
| Number of psychotropic medications | ||||||||||||||
| Baseline | 2.66 | 1.81 | 86.5 | 2.41 | 1.94 | 75.6 | 0.99 | 0.89–1.12 | –0.10 | 0.92 | 0.98 | 0.82–1.18 | –0.18 | 0.86 |
| 12 months | 1.58 | 1.52 | 65.2 | 2.23 | 1.93 | 68.8 | ||||||||
| 18 months | 1.77 | 1.65 | 68.3 | 2.21 | 1.72 | 72.1 | ||||||||
| 24 months | 1.81 | 1.72 | 66.1 | 2.04 | 1.89 | 64.8 | ||||||||
| 30 months | 1.98 | 1.88 | 65.5 | 1.95 | 2.00 | 58.3 | ||||||||
| 36 months | 1.65 | 1.78 | 60.4 | 2.39 | 2.16 | 67.8 | ||||||||
| Number of psychosocial treatments | ||||||||||||||
| Baseline | 1.53 | 1.35 | 82.0 | 1.46 | 1.17 | 79.8 | 1.51c | 1.18–1.59 | 3.28 | 0.001 | 1.53 | 0.99–2.34 | 1.95 | 0.05 |
| 12 months | 0.34 | 0.76 | 22.9 | 0.56 | 0.71 | 46.2 | ||||||||
| 18 months | 0.82 | 0.85 | 60.0 | 0.86 | 0.94 | 57.1 | ||||||||
| 24 months | 0.81 | 0.95 | 51.7 | 0.86 | 0.95 | 55.7 | ||||||||
| 30 months | 0.93 | 0.99 | 62.1 | 0.93 | 0.99 | 58.6 | ||||||||
| 36 months | 0.76 | 0.88 | 51.1 | 0.93 | 1.10 | 54.2 | ||||||||
a
Time-effect coefficients were based on generalized estimating equation analyses estimating step reduction between baseline and follow-up time points, and group-effect coefficients were based on generalized estimating equation analyses estimating differences by treatment group at follow-up visits.
b
The relative rate was calculated by using the parameter estimate of the general estimating equation model. As this was a logarithmic model, the exponential of this estimate is reported.
c
Significant after correcting for multiple comparisons.
The proportion of participants who reported any psychiatric hospitalization at each follow-up assessment ranged from 8.5% to 13.8% in the dialectical behavior therapy group and from 10.0% to 15.0% in the general psychiatric management group. The number of posttreatment admissions to psychiatric hospitals remained stable in both groups (z=–0.72, p=0.47), with no between-group differences (z=0.39, p=0.70). The total number of days in psychiatric hospitals remained unchanged from treatment to follow-up for both groups (z=0.49, p=0.63), and there were no between-group differences (z=0.09, p=0.93).
With regard to emergency department visits, the proportions at each follow-up assessment ranged from 24.0% to 43.1% for participants assigned to dialectical behavior therapy and from 27.1% to 36.7% for those assigned to general psychiatric management. The number of emergency department visits over the follow-up phase remained unchanged from treatment level for both groups (z=–1.60, p=0.11), and there were no between-group differences (z=–0.81, p=0.42.).
Participants in both groups showed similar patterns of psychotropic medication use, with the overall proportion for the entire sample across follow-up assessments ranging from 61.9% to 70.3%, compared with 81.0% at baseline. Participants assigned to the dialectical behavior therapy group reported a range from 1.65 to 1.98 psychotropic medications at each follow-up assessment, compared with 1.95 to 2.39 for those assigned to general psychiatric management. During follow-up, no significant differences in the average number of psychotropic medications used compared with the treatment phase were found between participants (z=–0.10, p=0.92). There were no between-group differences in the change in level of psychotropic medications reported (z=–0.18, p=0.86)
Suicidal and Nonsuicidal Self-Injurious Behaviors
Table 2 summarizes the frequency of suicidal and nonsuicidal self-injurious behaviors by group, with statistics based on generalized estimating equations. The effects of both treatments on the frequency and severity of these behaviors persisted after treatment. The proportion of participants reporting suicide attempts at each follow-up assessment ranged from 6.9% to 13.3% in the dialectical behavior therapy group and from 7.4% to 13.2% in the general psychiatric management condition. At 36 months, these proportions were 8.2% and 12.1%, respectively. The reduced rate of suicide attempts observed during the treatment phase was maintained for both groups during follow-up (z=0.47, p=0.64), and this did not differ between groups (z=–0.21, p=0.83). The proportion of participants who reported any nonsuicidal self-injurious behaviors during follow-up ranged from 24.5% to 38.6% in the dialectical behavior therapy condition and from 20.3% to 33.8% in the general psychiatric management condition. The effect of treatment on rates of nonsuicidal self-injurious behaviors was maintained after treatment for both groups (z=–1.82, p=0.07). The medical severity of these behaviors was unchanged from the end of treatment through the follow-up for both groups, indicating that treatment gains were maintained (t=0.78, df=933, p=0.44), and no between-group differences were found (t=1.50, df=933, p=0.14).
| Treatment Group | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dialectical Behavior Therapy (N=89) | General Psychiatric Management (N=88) | Time Effect for Follow-Up Phasea | Group Effect for Follow-Up Phase | |||||||||||
| Measures | Mean | SD | % | Mean | SD | % | Relative Rateb | 95% CI | z | p | Relative Rateb | 95% CI | z | p |
| Number of suicidal episodes | ||||||||||||||
| Baseline | 1.30 | 3.60 | 39.3 | 1.86 | 6.31 | 37.5 | 1.26 | 0.48–3.28 | 0.47 | 0.64 | 0.87 | 0.23–3.21 | –0.21 | 0.83 |
| 12 months | 0.33 | 1.31 | 10.1 | 0.32 | 2.09 | 6.6 | ||||||||
| 18 months | 0.27 | 0.80 | 13.3 | 0.54 | 2.26 | 13.2 | ||||||||
| 24 months | 0.07 | 0.26 | 6.9 | 0.09 | 0.33 | 7.4 | ||||||||
| 30 months | 0.14 | 0.69 | 7.0 | 0.24 | 0.84 | 10.2 | ||||||||
| 36 months | 0.55 | 2.42 | 8.2 | 0.29 | 1.15 | 12.1 | ||||||||
| Number of nonsuicidal self-injurious behaviors | ||||||||||||||
| Baseline | 21.65 | 35.20 | 84.3 | 20.41 | 39.98 | 87.5 | 0.56 | 0.30–1.05 | –1.82 | 0.07 | 1.17 | 0.35–3.87 | 0.26 | 0.80 |
| 12 months | 4.12 | 9.23 | 47.8 | 6.74 | 19.70 | 44.7 | ||||||||
| 18 months | 8.17 | 44.39 | 36.7 | 7.01 | 23.96 | 32.4 | ||||||||
| 24 months | 2.48 | 7.34 | 29.3 | 2.06 | 8.01 | 33.8 | ||||||||
| 30 months | 2.98 | 7.53 | 38.6 | 2.00 | 7.90 | 20.3 | ||||||||
| 36 months | 2.18 | 7.77 | 24.5 | 1.09 | 4.31 | 31.0 | ||||||||
a
Time-effect coefficients were based on generalized estimating equation analyses estimating step reduction between baseline and follow-up time points, and group-effect coefficients were based on generalized estimating equation analyses estimating differences by treatment group at follow-up visits.
b
The relative rate was calculated by using the parameter estimate of the general estimating equation model. As this was a logarithmic model, the exponential of this estimate is reported.
No participants died from suicide over the course of follow-up. There were two deaths from natural causes; both of those participants had been assigned to dialectical behavior therapy.
Secondary Clinical Outcomes
Table 3 summarizes secondary clinical outcomes based on mixed-effects linear growth-curve models. After treatment, participants in both groups showed either further improvements or maintenance of treatment effects on all outcomes. Figure 1 illustrates that the pattern of change from baseline to end of treatment was similar for both groups across a broad range of outcomes. After treatment, both groups showed further improvements in measures of anger, interpersonal functioning, and depression.
| Treatment Group | ||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Dialectical Behavior Therapy (N=90) | General Psychiatric Management (N=90) | Time Effect for Follow-Up Phase | Group Effect for Follow-Up Phase | |||||||||||
| Measure and Assessmenta | Mean | SD | Mean | SD | Coefficientb | 95% CI | t | df | p | Coefficientc | 95% CI | t | df | p |
| Maximum medical risk of suicide and self-injurious episodesd | ||||||||||||||
| Baseline | 2.86 | 1.21 | 2.63 | 1.27 | 0.01 | –0.02 to 0.04 | 0.78 | 933 | 0.44 | –0.03 | –0.07 to 0.01 | –1.50 | 933 | 0.14 |
| 12 months | 2.49 | 1.07 | 2.14 | 0.80 | ||||||||||
| 18 months | 2.93 | 2.45 | 2.54 | 1.27 | ||||||||||
| 24 months | 2.45 | 1.10 | 2.25 | 1.08 | ||||||||||
| 30 months | 2.08 | 0.83 | 2.63 | 1.26 | ||||||||||
| 36 months | 2.19 | 0.66 | 2.62 | 1.20 | ||||||||||
| Symptom severity (ZAN-BPD) | ||||||||||||||
| Total score | ||||||||||||||
| Baseline | 15.49 | 6.14 | 14.94 | 6.59 | –0.03 | –0.09 to 0.03 | –0.93 | 921 | 0.35 | 0.07 | –0.02 to 0.16 | 1.50 | 921 | 0.13 |
| 12 months | 7.93 | 6.11 | 8.16 | 5.79 | ||||||||||
| 18 months | 6.92 | 5.54 | 8.35 | 5.98 | ||||||||||
| 24 months | 8.17 | 6.10 | 8.09 | 5.89 | ||||||||||
| 30 months | 6.66 | 5.24 | 7.82 | 7.00 | ||||||||||
| 36 months | 8.29 | 6.35 | 6.66 | 5.49 | ||||||||||
| Cognitive subscale | ||||||||||||||
| Baseline | 3.64 | 2.01 | 3.97 | 2.10 | –0.01 | –0.03 to 0.01 | –1.10 | 923 | 0.27 | 0.02 | –0.01 to 0.05 | 1.08 | 923 | 0.28 |
| 12 months | 1.84 | 1.92 | 1.94 | 1.81 | ||||||||||
| 18 months | 1.80 | 1.89 | 2.15 | 1.95 | ||||||||||
| 24 months | 1.95 | 1.91 | 1.86 | 1.96 | ||||||||||
| 30 months | 1.54 | 1.76 | 1.98 | 2.24 | ||||||||||
| 36 months | 1.88 | 2.03 | 1.41 | 1.57 | ||||||||||
| Impulsivity subscale | ||||||||||||||
| Baseline | 2.76 | 1.96 | 2.36 | 1.81 | –0.001 | –0.02 to 0.02 | –0.50 | 923 | 0.95 | –0.001 | –0.02 to 0.02 | 0.09 | 923 | 0.92 |
| 12 months | 1.47 | 1.54 | 1.31 | 1.43 | ||||||||||
| 18 months | 1.25 | 1.31 | 1.09 | 1.35 | ||||||||||
| 24 months | 1.33 | 1.41 | 1.42 | 1.68 | ||||||||||
| 30 months | 1.09 | 1.24 | 1.27 | 1.46 | ||||||||||
| 36 months | 1.38 | 1.51 | 1.24 | 1.60 | ||||||||||
| Interpersonal subscale | ||||||||||||||
| Baseline | 3.06 | 1.94 | 2.70 | 1.86 | –0.01 | –0.03 to 0.01 | –1.05 | 921 | 0.29 | 0.02 | 0.0002 to 0.048 | 1.99 | 921 | 0.047 |
| 12 months | 1.47 | 1.43 | 1.65 | 1.48 | ||||||||||
| 18 months | 1.35 | 1.31 | 1.65 | 1.47 | ||||||||||
| 24 months | 1.52 | 1.47 | 1.63 | 1.49 | ||||||||||
| 30 months | 1.29 | 1.49 | 1.32 | 1.32 | ||||||||||
| 36 months | 1.77 | 1.84 | 1.34 | 1.53 | ||||||||||
| Affect subscale | ||||||||||||||
| Baseline | 6.03 | 2.33 | 5.92 | 2.67 | –0.01 | –0.04 to 0.02 | –0.68 | 923 | 0.50 | 0.03 | –0.01 to 0.07 | 1.43 | 923 | 0.15 |
| 12 months | 3.14 | 2.37 | 3.26 | 2.54 | ||||||||||
| 18 months | 2.72 | 2.49 | 3.47 | 2.52 | ||||||||||
| 24 months | 3.38 | 2.73 | 3.20 | 2.20 | ||||||||||
| 30 months | 2.75 | 2.27 | 3.25 | 2.93 | ||||||||||
| 36 months | 3.27 | 2.73 | 2.66 | 2.21 | ||||||||||
| Depression (BDI-II) | ||||||||||||||
| Baseline | 37.15 | 12.46 | 35.4 | 10.60 | –0.28e | –0.43 to –0.13 | –3.70 | 825 | 0.0002 | 0.32 | 0.10 to 0.54 | 2.89 | 825 | 0.004 |
| 12 months | 22.48 | 16.20 | 25.19 | 15.05 | ||||||||||
| 18 months | 21.00 | 16.68 | 23.05 | 14.94 | ||||||||||
| 24 months | 22.24 | 16.40 | 21.67 | 14.82 | ||||||||||
| 30 months | 20.76 | 16.82 | 19.31 | 15.33 | ||||||||||
| 36 months | 24.45 | 18.65 | 18.05 | 13.77 | ||||||||||
| Anger (STAXI, Anger Expression Scale score) | ||||||||||||||
| Baseline | 17.92 | 5.19 | 17.6 | 5.51 | –0.07e | –0.12 to –0.03 | –3.02 | 853 | 0.0006 | 0.07 | 0.01 to 0.14 | 2.23 | 853 | 0.02 |
| 12 months | 16.05 | 5.50 | 15.90 | 5.10 | ||||||||||
| 18 months | 16.13 | 5.20 | 15.38 | 4.63 | ||||||||||
| 24 months | 14.48 | 4.41 | 15.79 | 5.12 | ||||||||||
| 30 months | 15.70 | 4.43 | 14.84 | 3.93 | ||||||||||
| 36 months | 15.95 | 4.80 | 14.40 | 3.47 | ||||||||||
| Health status rating quality of life (EuroQol-5D Visual Analogue Scale) | ||||||||||||||
| Baseline | 57.19 | 21.93 | 55.29 | 19.41 | 0.29e | 0.08 to 0.50 | 2.71 | 843 | 0.007 | –0.28 | –0.59 to 0.04 | –1.72 | 843 | 0.09 |
| 12 months | 63.45 | 20.53 | 59.23 | 21.89 | ||||||||||
| 18 months | 64.40 | 21.60 | 60.55 | 21.53 | ||||||||||
| 24 months | 64.80 | 21.63 | 63.18 | 20.43 | ||||||||||
| 30 months | 64.44 | 22.20 | 63.75 | 18.23 | ||||||||||
| 36 months | 64.31 | 21.12 | 67.69 | 20.97 | ||||||||||
| Symptom distress (SCL-90-R total score) | ||||||||||||||
| Baseline | 1.91 | 0.77 | 1.85 | 0.76 | –0.01 | –0.02 to –0.01 | –3.42 | 836 | 0.006 | 0.01 | –0.002 to 0.02 | 1.54 | 836 | 0.12 |
| 12 months | 1.35 | 0.89 | 1.37 | 0.82 | ||||||||||
| 18 months | 1.23 | 0.91 | 1.31 | 0.85 | ||||||||||
| 24 months | 1.20 | 0.85 | 1.20 | 0.85 | ||||||||||
| 30 months | 1.24 | 0.84 | 1.16 | 0.83 | ||||||||||
| 36 months | 1.26 | 0.95 | 1.03 | 0.80 | ||||||||||
| Interpersonal functioning (IIP-64 total score) | ||||||||||||||
| Baseline | 119.00 | 44.02 | 121.30 | 37.13 | –0.82e | –1.19 to –0.44 | –4.29 | 833 | <0.0001 | 0.48 | –0.07 to 1.04 | 1.70 | 833 | 0.09 |
| 12 months | 100.85 | 50.52 | 102.99 | 45.61 | ||||||||||
| 18 months | 91.96 | 45.76 | 98.68 | 45.58 | ||||||||||
| 24 months | 94.93 | 49.88 | 97.11 | 48.46 | ||||||||||
| 30 months | 96.20 | 48.22 | 89.62 | 47.40 | ||||||||||
| 36 months | 94.48 | 47.96 | 84.36 | 45.46 | ||||||||||
a
ZAN-BPD=Zanarini Rating Scale for Borderline Personality Disorder; BDI-II=Beck Depression Inventory-II; STAXI=State-Trait Anger Expression Inventory; SCL-90-R=Symptom Checklist 90-Revised; IIP-64=Inventory of Interpersonal Problems–64.
b
Based on mixed-effects generalized linear regression analysis estimates of slope.
c
Based on mixed-effects generalized linear regression analysis estimates of change in slope by treatment group.
d
The medical risk is calculated using lethality of method and treatment received for each suicidal and self-injurious episode.
e
Significant after correction for multiple comparisons.
FIGURE 1. Outcomes for Dialectical Behavior Therapy (N=90) and General Psychiatric Management (N=90) Over 36 Months After Randomized Treatment Assignmenta
a ZAN-BPD=Zanarini Rating Scale for Borderline Personality Disorder; BDI-II=Beck Depression Inventory-II; STAXI=State-Trait Anger Expression Inventory; SCL-90-R=Symptom Checklist 90–Revised; IIP-64=Inventory of Interpersonal Problems–64. Estimates for the mean number of nonsuicidal self-injurious episodes and mean number of suicide attempts were derived from the generalized estimating equation models for assessing treatment effect. All other estimates come from mixed-effects models.
On measures of borderline psychopathology, both groups remained unchanged from the end of treatment, indicating that the treatment effects were sustained. Mixed-effects analyses of borderline symptom clusters revealed no differences from 12 to 36 months on affect (t=–0.68, df=923, p=0.50), cognitive (t=–1.10, df=923, p=0.27), impulsivity (t=–0.50, df=923, p=0.95), and interpersonal (t=–1.05, df=921, p=0.29) symptom clusters, and there were no between-group differences. One-year diagnostic remission of borderline personality disorder was achieved in 50% of participants in the dialectical behavior therapy group and in 55% of those in the general psychiatric management group at 24 months, and by 57% and 68%, respectively, at 36 months. There were no between-group differences in diagnostic remission rates after treatment.
On measures of general psychopathology, over the 2-year follow-up both groups maintained the benefits that had been achieved during treatment. Figure 2 illustrates the number of participants who achieved reliable change and clinically significant change as assessed on the SCL-90-R. Between baseline and 36-month follow-up, 63% of participants in the dialectical behavior therapy group and 70% in the general psychiatric management group achieved clinically reliable change, while 38% and 41%, respectively, fulfilled both criteria and could be considered recovered in a clinically significant way. There were no statistically significant between-group differences.
FIGURE 2. Clinically Relevant Change, by Treatment Assignment, 24 and 36 Months After Randomized Treatment Assignmenta
a Individuals in the gray zone achieved reliable change and clinically significant change as assessed on the Symptom Checklist 90–Revised (SCL-90-R).
With regard to health-related quality of life, scores on the EuroQol-5D were in the poor range at baseline, and while both groups showed significant improvements during the follow-up phase (slope=0.29, t=2.17, df=843, p=0.007), their scores remained below normal and in a range comparable to patients with comorbid major depression and anxiety disorders (29). No significant between-group differences were found (t=–1.72, df=843, p=0.09). Importantly, 51.8% of the sample were neither working nor in school at the end of follow-up, compared with 60.3% at the beginning of treatment. In the dialectical behavior therapy group, 57.9% were working or in school, compared with 40.4% of the general psychiatric management group. No between-group differences were found. Before treatment, 39.7% of the participants had been receiving psychiatric disability benefits (48.2% of those in dialectical behavior therapy and 40.3% of those in general psychiatric management), compared with 38.8% at the end of follow-up. At the end of follow-up, 29.0% of the dialectical behavior therapy group and 46.8% of the general psychiatric management group were supported by psychiatric disability benefits, and there were no between-group differences.
The pattern of results was not altered after removing from the analysis the three participants who received study treatment during the follow-up phase, nor after removing participants who received less than 8 weeks of treatment.
Discussion
Two years after treatment, participants in both groups exhibited sustained benefits of the 1-year intervention. The effects of treatment persisted on all assessed outcomes, including the frequency and severity of suicidal and nonsuicidal self-injurious behaviors, decreased health service utilization, symptom severity, and general psychopathology. Participants also continued to improve during follow-up on measures of interpersonal functioning, anger, depression, and quality of life. However, although quality of life increased after treatment, participants still exhibited considerable functional impairment, as indicated by low rates of full-time employment and continuing high reliance on psychiatric disability benefits.
These findings are noteworthy because they confirm that the effects of both treatments extend beyond initial symptom relief and are associated with long-lasting changes across a broad range of outcomes. The findings from this trial add to a growing number of studies (1, 2, 7, 30) demonstrating the sustained benefits of specific forms of manualized psychotherapies delivered by trained clinicians working within a team. The effects of treatment did not diminish over time for either group, suggesting that participants continued to derive benefits from what they had gained in treatment. Over time, participants became less depressed, had less anger, and had better interpersonal functioning, which we speculate was because of the treatments' shared focus on enhancing patients' emotion regulation capacities.
The overall rate of diagnostic remission 2 years after treatment (62%) was higher than the rate attained over a comparable time frame (42%) in another prospective follow-up study of borderline personality disorder (10). Disorder-specific treatments likely hastened recovery, underscoring the value of such treatments.
No differences between treatment conditions were found on any outcomes in our study. In contrast to previous studies comparing specific psychotherapy to nonspecific forms, we compared two manualized psychotherapeutic approaches that were specifically developed for borderline personality disorder and delivered by clinicians with expertise. Considering the field of psychotherapy outcome research more broadly, our findings are consistent with evidence that the number of true differences between psychotherapies developed for specific disorders is zero. Future research needs to be directed toward understanding the effective mechanisms of these two treatments. One possible explanation for the absence of differences between the treatments is that there are common factors that account for the effectiveness of both. We speculate that one common active ingredient is the inclusion of protocols designed to de-escalate suicide crises.
The high rate of unemployment (52%) and reliance on disability benefits (39%) among our participants at the 36-month follow-up is consistent with other follow-up studies (10–12), which indicates that poor psychosocial functioning persists even after symptomatic problems diminish. While the dialectical behavior therapy group had more participants who were employed and not on disability at 36 months, between-group differences were not statistically significant, suggesting insufficient power. Future research should be powered to test improvements in functioning, to examine barriers to engaging in productive functioning, such as financial disincentive of reemployment or stigma, and to test therapies designed to improve functioning in patients with borderline personality disorder.
Strengths of this study include the fact that it is the largest treatment follow-up study for borderline personality disorder, the design is prospective, and the sample is well characterized. The follow-up time frame is reasonably longer than those used in other studies of dialectical behavior therapy, and the follow-up rates were good, with 83% of participants attending at least 1 assessment and providing complete data on 3.5 of four assessments. In addition, the assessments were based on face-to-face interviews, the assessors were blind to treatment assignment, and the outcomes were diverse and broad and were assessed with standardized measures.
One limitation of our study is that data were not available for every participant at each assessment. However, because our sample was relatively large, the study remained adequately powered to detect differences even with missing data. Furthermore, the statistical methods used to analyze outcomes are based on all available data from all participants. Another limitation is that it is possible that the participants who were lost to follow-up were doing poorly, and the loss of their data may have biased the outcomes in a positive direction. It should also be noted that since this was a naturalistic study, access to treatments (with the exception of the study treatments) was uncontrolled. Additionally, self-report of treatment history and suicidal behavior may be subject to response biases. Approximately half of all participants reported receiving treatment during the follow-up phase, and this may have affected outcomes. Finally, in the absence of a control group undergoing no treatment, the natural course of the disorder is not known.
There are several directions for future research. For example, modeling individual trajectories can help to detect different patterns of treatment response. Additionally, given the lack of availability of effective treatments for borderline personality disorder, research is needed on the effectiveness of less-intensive models of care in order to help inform decisions about the allocation of scarce health care resources.
Patient Perspectives
Dialectical Behavior Therapy
A 32-year-old man with a lengthy history of psychiatric hospital admissions and visits to the emergency department was randomly assigned to the dialectical behavior therapy group. His history included chronic suicidal and self-injurious behaviors ranging from low to high lethality and dating back to the age of 10. He reported cutting and burning himself several times a week in an effort to relieve emotional pain. He had been treated for 8 years for dissociative identity disorder and had tried numerous medications without success. As a consequence of his chronic self-injurious behaviors and other dramatic conduct, he had few friends and was feeling miserable. The patient was referred to the study after presenting to psychiatric emergency services with suicidal behavior. During his first session, the patient's behavior was dramatic: he was initially nonresponsive when spoken to, made loud vocalizations upon seeing a fly on the wall, and later spoke in a quiet, childlike voice, referring to himself as “we.” Although initially he stated that he wanted to die, he acknowledged that he wanted a better life for himself and he committed to work on eliminating self-injurious and suicidal behaviors. He was also interested in improving his relationships, and he agreed to address bizarre behaviors, such as screaming, that were isolating him from others and compromising his engagement in treatment. Early in therapy, the focus was on analyzing and addressing the factors contributing to his indirect communication and dissociative behaviors.
Dialectical behavior therapy was very helpful for this patient. He learned that his unhealthy behaviors were a way of coping with unexpressed feelings; for example, overwhelming feelings of shame in response to perceived criticism were a frequent trigger to angry outbursts and self-harm behaviors. Over the course of treatment, he became less critical of himself, more trusting of his emotional responses, more tolerant of being alone, more confident and assertive, and less overwhelmed by painful emotions such as shame. Becoming less avoidant of his emotions, he could more effectively identify and address his needs. His relationships with others improved, and he became less prone to angry outbursts. His communication was more direct, and his pseudodissociative behaviors and suicidal and self-injurious behaviors ceased. Toward the end of treatment, his relationship with his partner improved. He enrolled in continuing education courses to upgrade his skills and began looking for a better job.
General Psychiatric Management
A 42-year-old woman with a history of suicidal behavior, binge drinking, marijuana abuse, and episodes of depression was randomly assigned to the general psychiatric management group. Leading up to her involvement in the study, the patient was having frequent crises accompanied by intense suicidal ideation, anxiety, and despair, during which she typically turned to alcohol and marijuana.
At the start of the trial, the patient was adamant that attention needed to be entirely on the medical management of her episodes of depression. She quickly developed a strong alliance with her psychiatrist, who validated her concern about bringing her depressive symptoms under control. Accordingly, parts of each session were given to monitoring or altering her antidepressant regimen, and she became more stable. As the single mother of a teenage son, she received various acknowledgments of her success at parenting; for example, her son was given an excellent letter of reference from his summer employer. When the therapist underlined her positive attributes, the patient was able to assimilate these acknowledgments as part of her own achievement of being a good mother. By examining her mothering abilities, she began to recognize the feelings of anger and rebelliousness that she had held toward her own parents and most authority figures. She articulated that acting rebellious had ensured that she would be “unlovable,” something she had always felt about herself. With greater insight into her rebellious attitude, the patient made a conscious effort to comply more faithfully with her medication. By the time the study came to a close, she had experienced only a few minor crises, and with encouragement had become much more social, particularly over the Internet. Over the follow-up period, she improved and continued the complex regimen of antidepressant medication under the care of an outpatient psychiatrist.
Acknowledgments
The authors thank Dr. Susan Wnuk, Joshua Murray, and numerous research analysts, volunteers, and colleagues at the Centre for Addiction and Mental Health, St. Michael's Hospital, and the University of Toronto Department of Psychiatry.
Footnotes
Received Sept. 22, 2011; revisions received Dec. 10, 2011, and Jan. 30, 2012; accepted Feb. 6, 2012.
Clinicaltrials.gov identifier: NCT00154154.
References
1.
Bateman A, Fonagy P: 8-year follow-up of patients treated for borderline personality disorder: mentalization-based treatment versus treatment as usual. Am J Psychiatry 2008; 165:631–638
2.
Davidson KM, Tyrer P, Norrie J, Palmer SJ, Tyrer H: Cognitive therapy v usual treatment for borderline personality disorder: prospective 6-year follow-up. Br J Psychiatry 2010; 197:456–462
3.
Kleindienst N, Limberger MF, Schmahl C, Steil R, Ebner-Priemer UW, Bohus M: Do improvements after inpatient dialectical behavioral therapy persist in the long term? a naturalistic follow-up in patients with borderline personality disorder. J Nerv Ment Dis 2008; 196:847–851
4.
Linehan MM, Heard HL, Armstrong HE: Naturalistic follow up of a behavioral treatment for chronically parasuicidal borderline patients. Arch Gen Psychiatry 1993; 50:971–974
5.
Linehan MM, Schmidt H, Dimeff LA, Craft JC, Kanter J, Comtois KA: Dialectical behavior therapy for patients with borderline personality disorder and drug-dependence. Am J Addict 1999; 8:279–292
6.
Linehan MM, Dimeff LA, Reynolds SK, Comtois KA, Welch SS, Heagerty P, Kivlahan DR: Dialectical behavior therapy versus comprehensive validation therapy plus 12-step for the treatment of opioid-dependent women meeting criteria for borderline personality disorder. Drug Alcohol Depend 2002; 67:13–26
7.
Linehan MM, Comtois KA, Murray AM, Brown MZ, Gallop RJ, Heard HL, Korslund KE, Tutek DA, Reynolds SK, Lindenboim N: Two-year randomized controlled trial and follow-up of dialectical behavior therapy vs therapy by experts for suicidal behaviors and borderline personality disorder. Arch Gen Psychiatry 2006; 63:757–766
8.
van den Bosch LMC, Koeter MWJ, Stijnen T, Verheul R, van den Brink W: Sustained efficacy of dialectical behavior therapy for borderline personality disorder. Behav Res Ther 2005; 43:1231–1241
9.
McMain SF, Links PS, Gnam WH, Guimond T, Cardish RJ, Korman L, Streiner DL: A randomized trial of dialectical behavior therapy versus general psychiatric management for borderline personality disorder. Am J Psychiatry 2009; 166:1365–1374
10.
Gunderson JG, Stout RL, McGlashan TH, Shea MT, Morey LC, Grilo CM, Zanarini MC, Yen S, Markowitz JC, Sanislow C, Ansell E, Pinto A, Skodol AE: Ten-year course of borderline personality disorder: psychopathology and function from the collaborative longitudinal personality disorders study. Arch Gen Psychiatry 2011; 68:827–837
11.
Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G: Time to attainment of recovery from borderline personality disorder and stability of recovery: a 10-year prospective follow-up study. Am J Psychiatry 2010; 167:663–667
12.
Zanarini MC, Frankenburg FR, Reich DB, Fitzmaurice G: The 10-year course of psychosocial functioning among patients with borderline personality disorder and axis II comparison subjects. Acta Psychiatr Scand 2010; 122:103–109
13.
First MB, Spitzer RL, Gibbon M, Williams JBW: Structured Clinical Interview for DSM-IV Axis I Disorders–Patient Edition (SCID-P). New York, New York State Psychiatric Institute, Biometrics Research Department, 1995
14.
Linehan MM: The Skills Training Manual for Treating Borderline Personality Disorder. New York, Guilford, 1993
15.
Linehan MM: Cognitive Behavioral Treatment of Borderline Personality Disorder. New York, Guilford, 1993
16.
American Psychiatric Association: Practice Guideline for the Treatment of Patients With Borderline Personality Disorder. Am J Psychiatry 2001; 158(Oct suppl)
17.
Kolla NJ, Links PS, McMain S, Streiner DL, Cardish R, Cook M: Demonstrating adherence to guidelines for the treatment of patients with borderline personality disorder. Can J Psychiatry 2009; 54:181–189
18.
Loranger AW: International Personality Disorder Examination (IPDE) Manual. White Plains, NY, Cornell Medical Center, 1995
19.
Linehan MM, Comtois KA, Brown MZ, Heard HL, Wagner A: Suicide Attempt Self-Injury Interview (SASII): development, reliability, and validity of a scale to assess suicide attempts and intentional self-injury. Psychol Assess 2006; 18:303–312
20.
Zanarini MC, Vujanovic AA, Parachini EA, Boulanger JL, Frankenburg FR, Hennen J: Zanarini Rating Scale for Borderline Personality Disorder (ZAN-BPD): a continuous measure of DSM-IV borderline psychopathology. J Pers Disord 2003; 17:233–242
21.
Derogatis LR: SCL-90-R Administration, Scoring and Procedure Manual. Towson, Md, Clinical Psychometric Research, 1983
22.
Spielberger CD: Manual for the State-Trait Anger Expression Inventory. Odessa, Fla, Psychological Assessment Resources, 1988
23.
Beck AT, Steer RA, Brown GK: Manual for Beck Depression Inventory II. San Antonio, Tex, Psychological Corporation, 1996
24.
Horowitz LM: Interpersonal Foundations of Psychopathology. Washington, DC, American Psychological Association, 2004
25.
EuroQol Group: EuroQol: a new facility for the measurement of health-related quality of life. Health Policy 1990; 16:199–208
26.
Singer JD, Willett JB: Applied Longitudinal Data Analysis: Modeling Change and Event Occurrence. New York, Oxford University Press, 2003
27.
Jacobson NS, Roberts LJ, Berns SB, McGlinchey JB: Methods for defining and determining the clinical significance of treatment effects: description, application, and alternatives. J Consult Clin Psychol 1999; 67:300–307
28.
Bohus M, Haaf B, Simms T, Limberger MF, Schmahl C, Unckel C, Lieb K, Linehan MM: Effectiveness of inpatient dialectical behavioral therapy for borderline personality disorder: a controlled trial. Behav Res Ther 2004; 42:487–499
29.
Supina AL, Johnson JA, Patten SB, Williams JV, Maxwell CJ: The usefulness of the EQ-5D in differentiating among persons with major depressive episode and anxiety. Qual Life Res 2007; 16:749–754
30.
Bateman A, Fonagy P: Treatment of borderline personality disorder with psychoanalytically oriented partial hospitalization: an 18-month follow-up. Am J Psychiatry 2001; 158:36–42
Information & Authors
Information
Published In
History
Received: 22 September 2011
Revision received: 10 December 2011
Revision received: 30 January 2012
Accepted: 6 February 2012
Published online: 1 June 2012
Published in print: June 2012
Authors
Funding Information
Dr. Links received an unrestricted educational grant from Eli Lilly Canada, Inc. The remaining authors report no financial relationships with commercial interests.Supported entirely by the Canadian Institutes for Health Research (grant 200204MCT-101123).
Metrics & Citations
Metrics
Citations
Export Citations
If you have the appropriate software installed, you can download article citation data to the citation manager of your choice. Simply select your manager software from the list below and click Download.
For more information or tips please see 'Downloading to a citation manager' in the Help menu.
View Options
View options
PDF/EPUB
View PDF/EPUBGet Access
Login options
Already a subscriber? Access your subscription through your login credentials or your institution for full access to this article.
Personal login Institutional Login Open Athens loginNot a subscriber?
PsychiatryOnline subscription options offer access to the DSM-5-TR® library, books, journals, CME, and patient resources. This all-in-one virtual library provides psychiatrists and mental health professionals with key resources for diagnosis, treatment, research, and professional development.
Need more help? PsychiatryOnline Customer Service may be reached by emailing [email protected] or by calling 800-368-5777 (in the U.S.) or 703-907-7322 (outside the U.S.).